Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer

NCT ID: NCT07152067

Last Updated: 2025-09-03

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 146 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2033-09-01

Brief Summary

*Rationale : Active surveillance of prostate cancer helps to avoid the morbidity associated with curative radical prostatectomy /radiotherapy in patients with early stage disease. However, at 5 years and 15 years, respectively 35 % and nearly 50 % of patients require rescue interventional treatments. Numerous Phase II trials have reported using focal treatments (focused on the macroscopic tumor only while not involving the whole prostatic gland) in order to reduce the morbidity due to recurrence as well as the high anxiety rates under observation only. Stereotactic radiotherapy (highly focused radiotherapy technic to reduce the risk of side effects) is being proposed in the same way as it does not require any anaesthesia, as opposed to all the other focal methods. The purpose of this trial is to evaluate whether focal stereotactic radiotherapy treatments could reduce the rate of rescue treatments among patients eligible to an active surveillance program at first.

• Major Inclusion Criteria :

• 1. Early stage prostate adenocarcinoma (CAPRA score ≤ 5)
• 2. No major urinary problems
• 3. Active Surveillance possible
• Major Exclusion Criteria :

• 1. Age at diagnosis < 50 years
• 8. Androgen-deprivation therapy
• 9. Any cancer within the last 5 years except skin basocellular carcinoma or any uncontrolled cancer
• Trial : Phase II randomized trial comparing Stereotactic Radiation Therapy focused on the macroscopic tumor or Active Surveillance as the control arm.
• Main objective : to compare the rescue treatment rates between the two arms

Detailed Description

The stereotactic radiation therapy procedure involves at first placement of 3-4 fiducial markers, a planning computed tomography (CT) scan as well as a planning MRI, both fused thereafter based on fiducial markers. The delay between fiducial markers placement and planning CT Scan - MRI must be of at least 10 days. SBRT delivers 36.25 Gy in 5 fractions prescribed on the 80% isodose or higher. The fractions are delivered with a CyberKnife device every other day for 2 weeks. If constraints to organs at risk can be fulfilled with other radiation therapy devices, the latter can be used for treatment as well. Organs-at-risk (rectal wall, bladder wall, bladder neck, urethra, as well as contralateral neurovascular bundles, contralateral external sphincter and contralateral pudendal vessels) are delineated (see constraints used in the first citation). Gross target volume (GTV) is delineated on the MRI while considering the hypointense T2-weighted nodule, the hypointense apparent diffusion coefficient, and the hyperintense perfusion zone. At first, the GTV is expanded by 1cm in all directions to generate the clinical target volume (CTV). The CTV is then cropped to the limits of the prostate. If the volume ratio CTV/Prostate is under 30%, the expansion margin of the GTV is increased progressively within the prostate by 0.1 cm increments so that the CTV achieves at least 30% of the prostate volume. Hence, a maximum of 1.5 cm margin around the GTV is allowed and encouraged. The CTV is then expanded by 3 mm to generate the planning target volume (PTV).

Conditions

Macroscopic Tumor Visualized at MRI; Tumor Size Allowing Partial Prostate Treatment Volume; CAPRA SCORE ≤5

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Active Surveillance

Active surveillance involving MRI, follow-up biopsies and PET PSMA exams

Group Type: NO_INTERVENTION

No interventions assigned to this group

Focal stereotactic radiation treatment

Focal radiation treatment followed by MRI, prostate biopsies and PET PSMA follow up exams

Group Type: EXPERIMENTAL

Stereotactic Body Radiation Therapy (SBRT)

Intervention Type: RADIATION

SBRT to the macroscopic prostate tumor component defined at MRI

Interventions

Stereotactic Body Radiation Therapy (SBRT)

SBRT to the macroscopic prostate tumor component defined at MRI

Intervention Type: RADIATION

Other Intervention Names

Focal stereotactic radiation treatment

Eligibility Criteria

Inclusion Criteria

• a. Localized prostate adenocarcinoma CAPRA score ≤ 5. This lesion is considered the Index lesion
• b. Macroscopic tumor PIRADS score >4 on multiparametric MRI
• c. The biopsies must be pathologic in or in the direct vicinity (the same prostatic zone defined as a quarter volume of the prostate (PZ)) of the MRI pathologic nodule
• d. The absence of MRI pathologic criteria (PIRADS ≤3) in a Gleason score ≤ 6 (3+3)-ISUP Grade1 zone outside of the single Index lesion is considered clinically non-significant and does not preclude inclusion
• e. The lesion can be plurifocal in a same intent to treat PZ
• f. WHO Performance Status 0-1
• g. No major urinary symptoms with IPSS score ≤15 and urinary continence ICIQ score =0
• h. Patient is candidate for AS

Exclusion Criteria

• a. Age at diagnosis < 50 years
• b. Time between initial diagnostic biopsies and randomization > 4 months, or radiation therapy initiation > 6 months
• c. Cribriform or Intraductal histologic components
• d. Gleason Score ≥7 (3+4)-ISUP Grade 2 biopsy outside the intent to treat PZ
• e. Multicentric pathologic MRI (PIRADS ≥4) outside a same PZ
• f. Initial PSA > 20 ng/ml
• g. Regional pathologic nodes or metastases
• h. Androgen-deprivation therapy
• i. Any cancer within the last 5 years except skin basocellular carcinoma or any uncontrolled cancer
• j. Urethral stenosis
• k. Recurrent prostatitis (at least 3 episodes within the last 3 years)
• l. Any inflammatory collagen disease.
• m. Contraindication to repeated prostatic biopsies or MRI

• Minimum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire de Liege

OTHER

Sponsor Role: lead

Responsible Party

NICKERS Philippe

Clinical Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Philippe Nickers, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Liège, Belgium

Mareva Lamande, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Liège, Belgium

Locations

Vivalia Hospitals

Arlon, , Belgium

University Hospital Liège

Liège, , Belgium

Countries

Belgium

Central Contacts

Mareva Lamande, MD

Role: CONTACT

mareva.lamande@chuliege.be

+3243233903

Sandra Tonneau, Secretary

Role: CONTACT

stonneau@chuliege.be

+3243237596

Facility Contacts

Annabelle Stainier, MD

Role: primary

annabelle.stainier@gmail.com

+3263551500

Mareva Lamande, MD

Role: primary

mareva.lamande@chuliege.be

+3243233903

Sandra Tonneau, Secretary

Role: backup

stonneau@chuliege.be

+3243237596

References

Nguyen PV, Donneaux B, Louis C, Bodgal Z, Philippi S, Biver S, Frederick B, Harze L, Lasar Y, Vogin G, Nickers P. Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: Results of a single-arm monocenter Phase-II trial. Front Oncol. 2023 Apr 6;13:1143716. doi: 10.3389/fonc.2023.1143716. eCollection 2023.

Reference Type: BACKGROUND

PMID: 37091187 (View on PubMed)

Newcomb LF, Schenk JM, Zheng Y, Liu M, Zhu K, Brooks JD, Carroll PR, Dash A, de la Calle CM, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Tretiakova MS, Wagner AA, Nelson PS, Lin DW. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA. 2024 Jun 25;331(24):2084-2093. doi: 10.1001/jama.2024.6695.

Reference Type: BACKGROUND

PMID: 38814624 (View on PubMed)

Hopstaken JS, Bomers JGR, Sedelaar MJP, Valerio M, Futterer JJ, Rovers MM. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. 2022 Jan;81(1):5-33. doi: 10.1016/j.eururo.2021.08.005. Epub 2021 Sep 4.

Reference Type: BACKGROUND

PMID: 34489140 (View on PubMed)

Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ, Bollina P, Doble A, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Paul A, Paez E, Powell P, Rosario DJ, Rowe E, Mason M, Catto JWF, Peters TJ, Oxley J, Williams NJ, Staffurth J, Neal DE; ProtecT Study Group. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023 Apr 27;388(17):1547-1558. doi: 10.1056/NEJMoa2214122. Epub 2023 Mar 11.

Reference Type: BACKGROUND

PMID: 36912538 (View on PubMed)

Other Identifiers

B7072025000023

Identifier Type: REGISTRY

Identifier Source: secondary_id

2025/176

Identifier Type: -

Identifier Source: org_study_id